Comparative Pharmacology
Head-to-head clinical analysis: LEVOXYL versus THYQUIDITY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LEVOXYL versus THYQUIDITY.
LEVOXYL vs THYQUIDITY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Levothyroxine is a synthetic thyroid hormone (T4) that is deiodinated to triiodothyronine (T3) in peripheral tissues, binding to thyroid hormone receptors in the nucleus and increasing metabolic rate, protein synthesis, and oxygen consumption.
Thyroid hormone replacement; levothyroxine (T4) is deiodinated to triiodothyronine (T3), which binds to thyroid hormone receptors, regulating gene transcription and increasing metabolic rate.
Initial adult dose: 25-50 mcg orally once daily; titrate by 12.5-25 mcg every 6-8 weeks based on TSH. Maintenance dose: 50-200 mcg orally once daily.
50 mg orally once daily, with or without food.
None Documented
None Documented
6-7 days in euthyroid patients; prolonged in hypothyroidism (9-10 days), shortened in hyperthyroidism (3-4 days); clinical steady-state after 6-8 weeks of consistent dosing.
The terminal elimination half-life of levothyroxine is approximately 6-7 days in euthyroid individuals. In hyperthyroidism, half-life decreases to 3-4 days; in hypothyroidism, it can extend to 9-10 days. This long half-life supports once-daily dosing and allows for steady-state achievement in about 6-8 weeks.
Renal (30-50% as unchanged drug and conjugates); fecal (biliary, 20-40% as conjugates); total clearance approximates 1-2 L/day in euthyroid patients.
Thyquidity (levothyroxine sodium) is primarily excreted via the kidneys as unchanged drug and metabolites. Approximately 20-40% of an oral dose is excreted in feces via biliary elimination, with the remainder eliminated renally. Up to 80% of an administered dose appears in urine as thyroxine and its metabolites, primarily glucuronide and sulfate conjugates.
Category C
Category C
Thyroid Hormone
Thyroid Hormone